Ignite Creation Date:
2025-12-24 @ 10:07 PM
Ignite Modification Date:
2026-06-08 @ 3:49 PM
Study NCT ID:
NCT00401635
Status:
COMPLETED
Last Update Posted:
2007-09-05
First Post:
2006-11-17
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
END-1: First Line Chemotherapy for Advanced or Recurrent Endometrial Carcinoma With Carboplatin and Liposomal Doxorubicin
Sponsor:
National Cancer Institute, Naples
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
END-1
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
None
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None